Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St

March 15, 2025

Sutro Biopharma (NASDAQ:STRO) Full Year 2024 Results

Key Financial Results

Revenue: US$62.0m (down 60% from FY 2023).
Net loss: US$227.5m (loss widened by 113% from FY 2023).
US$2.96 loss per share (further deteriorated from US$1.78 loss in FY 2023).

STRO Products In Clinical Trials

Phase II: 1.
Phase III: 1.

revenue-and-expenses-breakdown — NasdaqGM:STRO Revenue and Expenses Breakdown March 15th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sutro Biopharma Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 4.8%. Earnings per share (EPS) missed analyst estimates by 2.1%.

In the last 12 months, the only revenue segment was Development of Biopharmaceutical Products contributing US$62.0m. The largest operating expense was Research & Development (R&D) costs, amounting to US$239.5m (83% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$11.0m. Explore how STRO's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 46% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Sutro Biopharma (1 is a bit concerning) you should be aware of.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.